ERBB2 and breast cancer: Similarly, it has been shown that FITC-labeled trastuzumab allows to redirect AdCAR-T cells against epidermal growth factor receptor 2 (HER2)-expressing breast cancer cells, resulting in the eradication of established tumors in xenograft mouse models (14).